Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside
Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential opportunity. Click for more on TECX.
Tectonic Therapeutic reports ‘positive’ data from Phase 1b trial for TX45
Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate,
Tectonic Therapeutic stock soars on positive trial data
Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) surged 40% following the announcement of encouraging interim data from a Phase 1b trial for its TX45 treatment in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF).
Tectonic Therapeutic Shares Hit 52-Week High After Positive Trial Data
Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein.
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with
Tectonic jumps on positive data from early-stage trial for lead asset
Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer said that an early-stage trial for its lead candidate TX45 achieved its prespecified goals in a group of patients with pulmonary hypertension.
bovnews1d
Tectonic Therapeutics’ (TECX) Stock Rockets: What’s Behind the Surge?
Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its ...
BioSpace1d
Lilly Cuts Mid-stage Relaxin Study in Chronic Kidney Disease for ‘Lack of Foreseeable Clinical Benefit’
The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...
Seeking Alpha26d
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension, showing promise in early clinical trials. TX45's extended half-life and monthly ...
Investing2d
Tectonic shares tumble after rival drug trial termination
The market's reaction reflects concerns over the future of TECX's lead product candidate, TX45, which targets the same RXFP1 receptor as Lilly's volenrelaxin. The termination of Lilly's ...